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Abstract
Outbreaks of the Venezuelan Equine Encephalitis Virus 
(VEEV) and the Chikungunya Virus (CHIKV) continue to 
emerge in Central and South America, Africa, and Asia, but 
there are currently no vaccines or anti-virals for these viruses. 
Given their ease of transmission, debilitating symptoms, and 
genetic alterability, VEEV and CHIKV have great potential 
for development into biological weapons. Therefore, there 
is an urgent need to determine possible methods of treat-
ment or  prevention. One possibility of prevention lies in 
determining the structure and biological function of the E3 
protein that plays a key role in the infectivity of the viruses. 
In this research, heavy nitrogen (N15) labeling and nickel-
affinity  purification were used to purify E3 from VEEV. The 
 labeled E3 was used in nuclear magnetic resonance (NMR) to 
 determine secondary structure, but protein aggregation resulted 
in poor signal. Although various purification techniques, 
including cobalt-affinity purification, were used to obtain small 
amounts of E3 protein from CHIKV, further work is needed in 
order to obtain enough protein to be used for NMR analysis.
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INTRODUCTION
Origin and history
The Venezuelan Equine Encephalitis Virus (VEEV) 
infects both equines and humans and was first reported 
in donkeys, mules, and horses in the 1930s in South 
 America. Human cases were first documented in the 
1950s when a small outbreak occurred in Colombia 
 (Sanmartin-Barberi, Groot, & Osorno-Mesa, 1954, p. 
283). Viral outbreaks were localized to the regions of 
northern South America until the 1990s when the virus 
began to spread into Central America, and outbreaks 
have since been reported as far north as Mexico (Weaver, 
Ferro, Barrera, Boshell, & Navarro, 2004, p. 146).
The first case of the Chikungunya Virus (CHIKV) was 
reported in humans in 1953 in Tanzania  (Powers, Brault, 
Tesh, & Weaver, 2000, p. 471). Outbreaks  occurred 
throughout the 1960s and 1980s in several regions of 
Africa, and it is suggested that the virus spread to Asia 
as several outbreaks arose concurrently (Powers, et al., 
2000, p. 471). In the 2000s, cases have been  reported 
in various other regions including Europe, North 
 America, and  Australia (Powers & Logue, 2007, p. 2365). 
 Recently, large epidemics in India have caused concern 
about the growing rate of incidence (Pialoux, Gauzere, 
 Jauréguiberry, & Strobel, 2007, p. 319).
Although their mortality rates are low, each of these 
viruses causes health problems including rash, fever, 
arthritis, nausea, diarrhea, weakness, and fatigue, which 
often last for weeks (Weaver et al., 2004, p. 151). Because 
of their ability to incapacitate the infected, as well as 
the ease with which they can be genetically altered and 
transmitted, VEEV and CHIKV could easily be used as 
biological weapons. In 1959, Soviet scientists developed 
VEEV as a bioweapon and demonstrated the efficiency of 
aerosol transmission of the virus (Croddy, 2001, p. 211).
Existing treatments of the infection focus on  alleviating 
symptoms, but additional research could determine 
possible methods of preventing infectivity. In order for 
the viruses to infect cells, the E3 protein of the viruses 
must be separated from the precursor protein known as 
pE2. The E3 protein acts as a natural inhibitor to virus 
 penetration into cells; however, the biological function 
and three-dimensional structure of the E3 protein in 
VEEV and CHIKV is not known. Through determining 
the structure of the E3 protein, information on function 
could be obtained, or similar inhibitory molecules could 
be synthesized to prevent infection. 
Infection
Both VEEV and CHIKV are transmitted by mosquitoes, 
and symptoms begin to appear soon after the onset of 
infection. Most of the symptoms subside after a few days, 
but weakness can last for several weeks, and infection with 
VEEV can progress to encephalitis (Weaver et al., 2004, p. 151). 
Alphaviruses
VEEV and CHIKV are alphaviruses, which are  members 
of the Togaviridae family of viruses (Jose, Snyder, & 
Kuhn, 2009, p. 837). The alphaviruses are categorized 
as Old World or New World viruses. Old World viruses 
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Image 1. Surface of the Venezuelan Equine Encephalitis Virus. The spikes seen on the surface (yellow) are responsible 
for the virus binding to the host cell. A matrix of proteins (blue) surrounds the virus core, which contains the genome 
needed for virus production inside the host cell (Paredes, Alwell-Warda, Weaver, Chiu, & Watowich, 2001, p. 9534). 
Reproduced with permission from American Society of Microbiology.
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include Semliki Forest, Sindbis, and Chikungunya, 
which cause  symptoms such as rash, fever, arthritis, 
and weakness. New World viruses include Western 
Equine  Encephalitis, Eastern Equine Encephalitis, and 
 Venezuelan Equine  Encephalitis. These share the same 
symptoms as the Old World viruses, but can cause 
 encephalitis in the host (Jose, Snyder, & Kuhn, 2009, p. 837).
The viruses in the alphavirus family share many  structural 
similarities. Each alphavirus has an RNA genome that 
 encodes four nonstructural proteins and the capsid, E1, E2, 
E3, and 6K proteins. The virus core, called the  nucleocapsid, 
contains the genome surrounded by a lattice of capsid 
 proteins (Jose, Snyder, & Kuhn, 2009, p. 841). A lipid bilayer 
taken from the host cell during virus release surrounds the 
nucleocapsid (Jose, Snyder, & Kuhn, 2009, p. 838). Inserted 
into the bilayer are the viral glycoproteins E1 and E2, which 
form 80 spikes on the virus surface  (Paredes et al., 1993, p. 9096).
When the virus infects a cell, a cellular structure called the 
endosome contains the nucleocapsid. After the virus has 
entered the host cell, the nonstructural proteins are formed 
using the information in the viral genome. The nonstructural 
proteins replicate the genome and aid in the production of 
the capsid, E1, E2, E3, and 6K proteins. Initially, the E3 
and E2 proteins are linked and are called pE2. pE2 and E1 
pair up to form heterodimers or pE2/E1 pairs (Jose, Snyder, 
& Kuhn, 2009, p. 839). The pE2/E1  heterodimers are then 
moved through the cell to be displayed on the plasma 
membrane, or cell surface, of the host. At some point during 
movement, pE2 is separated into the E3 and E2 proteins 
(Strauss & Strauss, 1994, p. 504). At the plasma membrane, 
the E1/E2 heterodimers combine in groups of three that 
protrude from the virus and resemble spikes (Paredes et al., 
1998, p. 1538). Then the newly formed nucleocapsid buds 
from the host cell, taking part of the host’s lipid bilayer 
(plasma membrane) containing the E1/E2 glycoproteins 
(Jose, Snyder, & Kuhn, 2009, p. 838). The mature virus can 
then infect  another cell. Part of the E1 protein, called the 
fusion peptide, is responsible for nucleocapsid release from 
the endosome and occurs as a result of E2 dissociating from 
E1 in the acidic environment of the endosome. This process 
releases the nucleocapsid into the cell, and viral replication 
and protein production begins again.
The E3 protein
Although it is not well studied, the E3 protein appears to 
act as a natural inhibitor to viral entry and  infectivity. The 
E3 protein, after separation from E2, is a small protein 
roughly 7 kilodaltons in size (which is equal to approxi-
mately 100 quintillionth of a gram). The function of E3 
has not been entirely determined, but it is likely that it is 
needed for stabilization of the E1/E2 heterodimers  during 
movement to the cell surface (Jose, Snyder, & Kuhn, 
2009, p. 839). If E3 is removed from E2 prematurely, then 
the E1/E2 heterodimers will dissociate and the progeny 
viruses will lack the E1/E2 spikes, preventing them from 
 infecting other cells (Lobigs & Garoff, 1990, p. 1233). 
The  conformation of the pE2/E1 heterodimers protects the 
fusion peptide of E1 from premature exposure; however, 
when E3 is separated from E2 the conformation of E2 
changes and causes exposure of the fusion peptide (Voss 
et al., 2010, p. 711). These findings indicate that separation 
of E3 from E2 is necessary for exposure of the fusion 
 peptide. If pE2 is not separated into E2 and E3, it can 
still be incorporated into the spikes displayed on the 
virus  surface (Strauss & Strauss, 1994, p. 504). Because 
the fusion peptide of E1 is not exposed, the infectivity is 
very low (Strauss & Strauss, 1994, p. 504), resulting in no 
progeny virus production.
The reemergence of VEEV and CHIKV and the growing 
rate of incidence have caused great concern. Due to the 
ease of aerosol transmission, disease duration, and lack of 
prevention or treatment, the viruses pose a threat for use 
as biological weapons. If large numbers of a  population 
were infected, the severity of the symptoms could have a 
dramatic impact on the health and economy of a  country. 
For this reason, the study of the virus’ methods of 
 infectivity, particularly in regards to the significance of 
E3 in infection, is crucial. 
The aim of this research is to determine the structure of 
the E3 protein from VEEV and CHIKV. Knowledge of the 
E3 structure would also provide insight into the related 
viruses of the alphavirus genus and could  potentially 
be used to design a structurally similar drug that could 
prevent infection of the viruses in the same manner as E3. 
Additionally, the function and fate of E3 after cleavage 
from E2 is unclear, but structure can sometimes provide 
valuable information regarding the function of a protein. 
In order to learn about the structure and function of the 
E3 protein, protein purification techniques including 
nickel-affinity purification, cobalt-affinity purification, 
and anion-exchange purification were used to isolate 
large amounts of purified E3 to be used in the structural 
 analysis via nuclear magnetic resonance (NMR).
MATERIALS AND METHODS
Expression of the E3 protein
In order to obtain the E3 proteins from VEEV and 
CHIKV to do structural studies, the first task was to use a 
system to produce large amounts of the protein. Because 
of the hazards and difficulties in  obtaining the protein 
from the viruses, a system was designed to produce the 
protein in E.coli. Because of the internal environment 
of the E.coli cells, the E3 protein could not be  produced 
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without a protein that would add stabilization. To 
 accomplish this, the DNA sequence that encodes the E3 
protein as well as the sequence that encodes thioredoxin, 
a stabilizing protein, were linked and put into E.coli 
cells. Contained within the thioredoxin (Trx) sequence 
is a sequence for a his-tag (6XHis), which aids in the 
 purification of proteins from cells. The DNA sequence was 
put into E.coli cells, and the cells were forced to produce, 
or express, the protein. Large amounts of the recombinant 
protein (see Figure 1), which also contains a recognition 
sequence for TEV protease, were expressed in E.coli.
Purification of the E3 protein
Because E.coli normally expresses many different 
 proteins, the recombinant protein needed to be separated 
from the other proteins (see Figure 2). To accomplish 
this, the recombinant protein was isolated from E.coli 
by passing it through a nickel column. This process is 
called nickel-affinity purification. After the E.coli cells 
expressed large amounts of the recombinant protein, they 
were broken open, or lysed. The contents, which contained 
normal E.coli proteins, the recombinant protein, and DNA 
and RNA, were applied to a column containing nickel. 
In order to separate the thioredoxin protein (Trx) from 
the E3 protein, TEV protease was added to the protein, 
which cuts the linker region between Trx and E3 protein. 
After cleavage with TEV, the proteins were added onto 
the  nickel column again, but because the E3 protein then 
lacked the 6XHis tag, it was able to pass through the 
 column and be collected.
RESULTS AND DISCUSSION
Expression and purification of the recombinant 
protein from VEEV
To produce large amounts of the recombinant 
 protein  containing E3 from VEEV, referred to as 
 VEEVTrx-6XHis-E3, the DNA sequence for  VEEVTrx-6XHis-E3 
was put into E.coli cells, and the cells were forced to 
express VEEVTrx-6XHis-E3 for two hours at 37°C.  After 
expression, the cells were lysed, and the contents, 
called the lysate, were applied to a nickel column. After 
 removal from the column, the purified VEEVTrx-6XHis-E3 
was  incubated with TEV protease for 16 hours at room 
 temperature. The mixture of proteins was then applied 
to a nickel column, and the E3 protein (referred to as 
VEEVE3) was collected and subsequently purified on an 
anion-exchange column (see Figure 3).
Expression, purification, and structural analysis 
of heavy nitrogen labeled VEEVE3
Since large amounts of pure VEEVE3 were obtained, 
structural work could be started. In order to use NMR 
to determine the structure, the VEEVE3 had to be heavy 
Figure 2. Diagram of nickel-affinity purification. 
Left: The contents of the E.coli cells, called the lysate, which 
include DNA, RNA, normal E.coli proteins, and the  recombinant 
protein, are added to a column that contains nickel. The 6XHis 
of the recombinant protein binds tightly to the nickel and 
 remains stuck inside the column while the other cell  components 
lack 6XHis and can pass through and are discarded. The 
 recombinant protein is then removed from the column. 
Middle: The E3 protein needs to be separated from the 
 thioredoxin protein (Trx) and 6XHis in order to do structural 
analysis. TEV protease is added to the recombinant protein, 
which cuts, or cleaves, the protein into Trx-6XHis and E3. 
Right: The reaction mixture of TEV protease,  Trx-6XHis, and 
E3 is added to a nickel column. TEV protease also  contains 
6XHis and will stick to the column along with  Trx-6XHis, while 
the E3 protein does not and will pass thought the column 
and can be collected. The now purified E3 can be used for 
 structural analysis.
Figure 1. Diagram of the recombinant protein. The 
 recombinant protein contains thioredoxin protein (Trx) for 
 stabilization of E3 in E.coli, a 6XHis tag for purification, a TEV 
cut site, or cleavage site, for separation from Trx and 6XHis, 
and the E3 protein.
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nitrogen (N15) labeled. In order to label the protein, it 
was expressed in a minimal media supplemented with 
N15, so that all of the amino acids of the recombinant 
 protein would be labeled. The labeled recombinant 
protein,  referred to as VEEVTrx-6XHis-E3-N15, was expressed 
in  minimal media supplemented with N15 for two hours 
at 37°C, then for an additional 20 hours at 22°C. The 
VEEVTrx-6XHis-E3-N15 was then purified through nickel-
affinity purification. The purified VEEVE3-N15 was used 
to perform a HSQC, which determines secondary protein 
structure. The measurements were made at 4°C (see Figure 4).
In the figure, the signal is tightly clumped. This  indicates 
that VEEVE3-N15 has aggregated, and as a result no 
 information about the secondary structure could 
be  determined. Investigation into different solution 
 conditions (buffers) and additives is needed to prevent 
 aggregation, so that a better HSQC can be obtained.
Expression and nickel-affinity purification of the 
recombinant protein from CHIKV
After the success with the expression and purification of 
VEEVE3, the same techniques were applied to the puri-
fication of CHIKVE3. CHIKVTrx-6XHis-E3 was expressed at 
Figure 5. Purification of CHIKVE3. The expression of 
 CHIKVTrx-6XHis-E3 at zero hours (lane 1) and four hours (lane 2) 
at 37°C. The cell lysate containing CHIKVTrx-6XHis-E3 (lane 3) was 
 purified through nickel-affinity purification (lane 4), cleaved with 
TEV protease, and CHIKVE3 was then purified by nickel-affinity 
purification (lane 5).
Figure 3. Purification of VEEVE3. The expression of 
 VEEVTrx-6XHis-E3 at zero hours (lane 1) and two hours (lane 2) 
at 37°C. The cell lysate containing VEEVTrx-6XHis-E3 (lane 3) was 
purified through nickel-affinity purification (lane 4), cleaved with 
TEV protease, and VEEVE3 was then purified by nickel-affinity 
 purification and anion-exchange purification (lane 5).
Figure 4. HSQC of VEEVE3-N15 at 4°C.
37°C for four hours and was purified using nickel-affinity 
purification. CHIKVTrx-6XHis-E3 was cleaved with TEV for 
16 hours at room temperature and applied to a nickel 
 column and CHIKVE3 was collected (see Figure 5).
The expression of CHIKVTrx-6XHis-E3 yielded similar 
amounts of protein as the VEEVTrx-6XHis-E3 expression, and 
the nickel-affinity purification produced large amounts 
of relatively pure CHIKVTrx-6XHis-E3. Unfortunately, after 
TEV cleavage and subsequent purification, the yield of 
CHIKVE3 was very low.
 There are several possibilities as to why low yields 
of CHIKVE3 were obtained. The possibilities of low 
 concentration and purity of TEV and CHIKVTrx-6XHis-E3, 
as well as buffer conditions for the reaction, were tested 
and resulted in little improvement in the efficiency of the 
 reaction. This led to the conclusion that that CHIKVE3 
could be sticking to the sides of the tube used in the 
 cleavage reaction. To test this idea, CHIKVTrx-6XHis-E3 
was purified through cobalt-affinity purification, which 
is  similar to nickel-affinity purification, except cobalt is 
used in the column instead of nickel. This improved the 
purity of CHIKVTrx-6XHis-E3, and the TEV cleavage  reaction 
was set up using fresh TEV. After the reactions were 
 completed, the mixture was transferred into fresh tubes, 
and samples of the material from the sides of the old tubes 
were made (see Figure 6).
Interestingly, the material from the sides of the tube 
 contain either CHIKVTrx-6XHis-E3, TEV, or both, and 
 possibly CHIKVE3. This could explain why there has been 
poor cleavage efficiency and lack of CHIKVE3. If the TEV, 
CHIKVTrx-6XHis-E3, or both are sticking to the sides, they 
have less opportunity to contact each other for  cleavage. 
The CHIKVE3 would not be recovered because only the 
liquid mixture is applied to the nickel column. It is likely 
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that after cleavage CHIKVE3 becomes insoluble and sticks 
to the sides of the tube. Investigation into  different  buffers 
and different reaction tubes is needed to avoid this problem.
Conclusion
The optimal levels of VEEVTrx-6XHis-E3 expression at 37°C 
were reached within two hours, and large amounts of 
VEEVE3 were obtained from nickel-affinity purification 
and anion-exchange purification. Expression in minimal 
media of N15 labeled VEEVTrx-6XHis-E3 was successful, but 
HSQC to determine the secondary structure was not as 
a result of protein aggregation. More work is needed to 
identify buffer conditions that will prevent aggregation.
The optimal levels of CHIKVTrx-6XHis-E3 expression at 37°C 
were reached within four hours. However, CHIKVE3 
 appears to be sticking to the sides of the reaction tube, 
so more research is needed to fix the problem and to 
ensure that pure CHIKVE3 can be obtained and used for 
 structural analysis.
With further research, the structure of E3 from 
the  Venezuelan Equine Encephalitis Virus and the 
 Chikungunya Virus can be determined. This  information 
could be used by pharmaceutical companies to design 
drugs with similar structures that could prevent  infection 
in much the same manner as E3. With a potential 
 treatment, concern about the development of the viruses 
as biological warfare agents would be diminished, and the 
quality of health of individuals in geographic areas where 
the viruses persist would be greatly improved.
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